The adipocyte hormone leptin has a wide-scope of actions including regulation of weight and insulin sensitivity. We showed that leptin therapy in the setting of non-HIV lipodystrophy reverses insulin resistance, hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD). Subsequently, we have shown that 40% of male patients with nonalcoholic steatohepatitis (NASH, the most severe form of NAFLD) have relative leptin deficiency (RLD) by demonstrating a leptin level <25th percentile of BMI- and-gender-matched NHANES III cohort. We have recently completed a pilot study that investigated effects of leptin therapy in NASH and RLD. Preliminary data are encouraging to suggest that male patients with RLD are in fact leptin-responsive as they demonstrate salutary metabolic effects as well as histopathological improvement in liver with open-label leptin therapy. We now propose to explore RLD in NASH in a broader scale.
In Aim 1, we will test the efficacy of recombinant leptin therapy in 40 men with NAFLD/NASH and RLD against placebo whose diets will be controlled with moderate caloric restriction in a double-blind design for 1 year.
In Aim 2, we will investigate the time course of change that we have observed over resting energy expenditure (REE). We will also explore mechanisms of change in REE by studying autonomic function, thyroid axis and brown fat mass by performing FDG- PET scanning. If this proposal is completed successfully, results may offer new clinical and molecular insights into leptin action in humans.
In Aim 3, we will determine the differences in hepatic gene expression as well as serum metabolomic profiles. Preliminary data are showing interesting leads for a regulatory role for leptin in the hepatic FXR/RXR pathway. We will have the opportunity to investigate this in greater detail in a larger number of patients using a controlled diet and against placebo control.

Public Health Relevance

A growing complication of obesity is fatty liver disease, with least a third of the general population afflicted with this condition. Understanding the link between signals of adiposity (such as leptin) and fatty liver disease may help us improve our approaches to obesity and insulin resistance. If our hypotheses are correct, 20% of people with fatty liver disease (those with relative leptin deficiency) may derive direct clinical benefit from implications of our research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK088114-02
Application #
8220799
Study Section
Clinical and Integrative Diabetes and Obesity Study Section (CIDO)
Program Officer
Doo, Edward
Project Start
2011-02-05
Project End
2015-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
2
Fiscal Year
2012
Total Cost
$338,213
Indirect Cost
$120,713
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Lager, Corey J; Esfandiari, Nazanene H; Subauste, Angela R et al. (2017) Milestone Weight Loss Goals (Weight Normalization and Remission of Obesity) after Gastric Bypass Surgery: Long-Term Results from the University of Michigan. Obes Surg 27:1659-1666
Lager, Corey J; Esfandiari, Nazanene H; Subauste, Angela R et al. (2017) Roux-En-Y Gastric Bypass Vs. Sleeve Gastrectomy: Balancing the Risks of Surgery with the Benefits of Weight Loss. Obes Surg 27:154-161
Ajluni, Nevin; Meral, Rasimcan; Neidert, Adam H et al. (2017) Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clin Endocrinol (Oxf) 86:698-707
Chan, Jean L; Koda, Joy; Heilig, Joseph S et al. (2016) Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Clin Endocrinol (Oxf) 85:137-49
Habers, G Esther A; Huber, Adam M; Mamyrova, Gulnara et al. (2016) Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. Arthritis Rheumatol 68:761-8
Ajluni, Nevin; Dar, Moahad; Xu, John et al. (2016) Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program. J Diabetes Metab 7:
Brown, Rebecca J; Araujo-Vilar, David; Cheung, Pik To et al. (2016) The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab 101:4500-4511
Lebastchi, Jasmin; Ajluni, Nevin; Neidert, Adam et al. (2015) A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin. J Clin Endocrinol Metab 100:3967-70
Subauste, Angela R; Esfandiari, Nazanene H; Qu, Yunyan et al. (2014) Impact of left ventricular assist device on diabetes management: an evaluation through case analysis and clinical impact. Hosp Pract (1995) 42:116-22
Huber, Adam M; Mamyrova, Gulnara; Lachenbruch, Peter A et al. (2014) Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 66:732-40

Showing the most recent 10 out of 18 publications